Sino Biopharmaceutical (HK:1177) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sino Biopharmaceutical has acquired a 4.91% equity stake in LaNova Medicines with an investment of RMB142 million, marking a strategic partnership to advance innovative cancer treatments. This collaboration aims to expedite the development and commercialization of LaNova’s promising drug pipeline, including the groundbreaking LM-108 monoclonal antibody targeting multiple cancers. The investment underscores Sino Biopharmaceutical’s commitment to enhancing its oncology portfolio and supporting innovative cancer therapies.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
